robatumumab
mAbexperimental
Robatumumab is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00551213)
Timeline
Indications
Mechanism of action
- Insulin-like growth factor I receptorANTAGONIST
IGF1R antagonist
IGF1R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRobatumumab ↗
- ChEMBLCHEMBL1743064 ↗
Also known as
- 19d12
- robatumumab
- robatumumab
- robatumumab
- robatumumab
- sch717454
- sch 717454
- sch-717454
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00960063 | Phase 1 | Nov 11, 2009 | Merck |
| NCT00954512 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2009 | Merck |
| NCT00617890 | Phase 2 | Feb 1, 2008 | Merck |
| NCT00551213 | Phase 2 | Nov 1, 2007 | Merck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 4 | 4 | 2 | 2007 |
1 organizations
Page 1 / 1